Without insurance, Wegovy's list price in 2026 sits at approximately $1,350–$1,650 per month depending on your dose and pharmacy. Most uninsured patients do not pay full list price — manufacturer coupons, patient assistance programs, and pharmacy discount cards can bring that number down significantly, sometimes to as little as $0 for eligible patients.
What Is the Wegovy List Price in 2026?
Novo Nordisk sets Wegovy's Wholesale Acquisition Cost (WAC), which is the baseline price before any discounts or negotiations. As of 2026, the WAC for a four-week supply of Wegovy — regardless of dose — is approximately $1,349 to $1,650. Pharmacies add their own dispensing fees and markups, so the price you see at the counter may vary by $50–$150 between retailers.
Wegovy comes in five injection pen doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. All dose strengths carry a similar monthly price, which means your cost during the lower starter doses is roughly the same as at your full maintenance dose of 2.4 mg.
Most important takeaway: Never pay full list price without first checking the Novo Nordisk savings card and NovoCare patient assistance program. Eligible commercially insured — and even some uninsured — patients can reduce their monthly cost to as low as $0 through these programs.
How Does the Dose Escalation Schedule Affect What You Pay?
The FDA-approved Wegovy dose escalation lasts approximately 16 weeks before you reach the 2.4 mg maintenance dose. Per the prescribing information, doses increase every four weeks. Because each tier is priced similarly, your monthly out-of-pocket cost remains fairly consistent throughout the ramp-up period — unlike some other medications where higher doses cost more.
| Weeks | Dose | Approx. Monthly List Price | With Novo Savings Card* |
|---|---|---|---|
| Weeks 1–4 | 0.25 mg | ~$1,350–$1,650 | As low as $0–$25 |
| Weeks 5–8 | 0.5 mg | ~$1,350–$1,650 | As low as $0–$25 |
| Weeks 9–12 | 1 mg | ~$1,350–$1,650 | As low as $0–$25 |
| Weeks 13–16 | 1.7 mg | ~$1,350–$1,650 | As low as $0–$25 |
| Week 17 onward | 2.4 mg (maintenance) | ~$1,350–$1,650 | As low as $0–$25 |
*Savings card eligibility and cap amounts are subject to Novo Nordisk program terms and may change. Commercial insurance is typically required; government-insured patients (Medicare, Medicaid) are not eligible.
What Savings Programs Can Reduce Your Cost?
Several legitimate programs exist specifically to help patients afford Wegovy. Here are the main options:
- Novo Nordisk Savings Card: For commercially insured patients, this card can reduce your monthly cost to as little as $0 for up to 24 months of treatment. Eligibility and benefit caps apply. Apply at wegovy.com.
- NovoCare Patient Assistance Program: Uninsured or underinsured patients who meet income guidelines may qualify to receive Wegovy at no cost. Income thresholds and documentation are required. Visit novocare.com to apply.
- GoodRx and pharmacy discount cards: GoodRx prices for Wegovy typically range from $1,100 to $1,400 per month — a modest reduction from list price, but far less impactful than the Novo savings card. These cards are most useful if you don't qualify for manufacturer programs.
- Telehealth and mail-order pharmacies: Some telehealth platforms negotiate bulk pricing with mail-order pharmacies. Prices vary widely; always verify you are receiving FDA-approved brand-name Wegovy and not an unlicensed compound.
Is Compounded Semaglutide a Cheaper Alternative?
During periods when Wegovy appeared on the FDA drug shortage list, compounding pharmacies were legally permitted to produce semaglutide copies. However, the FDA declared the semaglutide shortage resolved in 2024 and issued guidance indicating that compounded copies of FDA-approved drugs like Wegovy generally cannot be legally marketed when a shortage no longer exists. As of 2026, patients should exercise significant caution with compounded semaglutide products.
Compounded versions may appear substantially cheaper — sometimes $200–$400 per month — but they are not FDA-approved, have not been tested for safety and efficacy in the same way, and may contain incorrect dosing or impurities. The FDA has warned consumers about these risks publicly. If cost is a barrier, the NovoCare assistance program is a safer path to explore first.
How Does Wegovy's Price Compare to Other GLP-1 Medications?
Understanding how Wegovy sits in the broader GLP-1 landscape can help you have a more informed conversation with your prescriber about alternatives.
- Ozempic (semaglutide 2 mg, for type 2 diabetes): List price approximately $900–$1,000/month. Approved for diabetes, not obesity — but some providers prescribe it off-label. Its savings card is separate from Wegovy's.
- Mounjaro / Zepbound (tirzepatide): Zepbound, the obesity-approved version, carries a similar list price to Wegovy (~$1,050–$1,300/month). Eli Lilly's savings card for Zepbound has offered prices as low as $25/month for eligible patients. The SURMOUNT-1 trial published in the New England Journal of Medicine (Jastreboff et al., 2022) showed tirzepatide produced greater average weight loss than semaglutide in head-to-head analysis context, though direct comparative trials have since been conducted.
- Rybelsus (oral semaglutide): Approved for type 2 diabetes only; not FDA-approved for weight loss.
Frequently Asked Questions
Wegovy's list price is high, but most uninsured or underinsured patients have real options to reduce what they pay — from manufacturer assistance programs to legitimate discount cards. The key is knowing which programs you qualify for before you fill your first prescription. Talk to your prescriber or a patient services representative at Novo Nordisk about your specific financial situation, insurance status, and which savings pathway makes the most sense for you. Your prescriber can also discuss whether an alternative GLP-1 medication might be both clinically appropriate and more affordable given your coverage.
- FDA Wegovy (semaglutide) Prescribing Information, revised 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
- Novo Nordisk Wegovy Savings Offer
- SURMOUNT-1 Trial: Jastreboff AM et al. 'Tirzepatide Once Weekly for the Treatment of Obesity.' NEJM 2022;387(3):205-216.
- STEP 1 Trial: Wilding JPH et al. 'Once-Weekly Semaglutide in Adults with Overweight or Obesity.' NEJM 2021;384(11):989-1002.
- GoodRx Wegovy price estimates. https://www.goodrx.com/wegovy
- FDA Statement on Compounded Semaglutide, 2024
- NovoCare Patient Assistance Program